<DOC>
	<DOCNO>NCT01644201</DOCNO>
	<brief_summary>One two adult Canada currently overweight therefore increase risk number medical condition include diabetes , high blood pressure , heart attack stroke . Obesity less prevalent population consume large amount dietary fibre , suggest fibre intake could play important role prevention progression obesity diabetes condition . Several study suggest fibre positive effect blood sugar may help low body weight . The purpose study help good understand effect add fibre supplementation low calorie diet blood sugar control weight loss . The investigator hypothesize blood sugar control improve participant fibre supplementation group . Men woman , stable Type 2 Diabetes ( e.g . medication change last 3 month ) , 18 - 75 year age , Body Mass Index ( BMI ) 27 - 60 kg/m2 participate study .</brief_summary>
	<brief_title>A Study Evaluating Effects High Viscosity Non-starch Polysaccharide ( PolyGlycopleX® - PGX® ) Glycemic Control , Cardiometabolic Risk Factors Weight Loss Overweight Obese Type II Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1875 year age ( &gt; 65 year age , enrolment discretion qualify investigator ) BMI 2760 Kg/m2 Stable Type 2 diabetes mellitus ( i.e . medication change last 3 month ) Ability provide write informed consent accordance Good Clinical Practice ( GCP ) local legislation HbA1c &lt; 7.0 % &gt; 10.0 % History bariatric surgery &gt; 10 Kg weight gain weight loss past 3 month Known eat disorder Participant take weight loss medication last 3 month ( eg . Meridia , Xenical ) Participant take follow medication alter body weight appetite : Antipsychotics neuroleptic Prednisone Antidepressants Tricyclic amitriptyline , imipramine ( Tofranil ) , doxepin ( Sinequan ) Monoamine oxidase inhibitor ( MAOIs ) tranylcypromine , ( Parnate ) , isocarboxazid ( Marplan ) phenelzine ( Nardil ) Tetracyclic Mirtazapine ( Remeron ) Serotonin antagonist reuptake inhibitor ( SARI ) Trazodone Note : The follow antidepressant NOT exclusion medication : SSRIs citalopram ( Celexa ) , escitalopram ( Lexapro ) , fluvoxamine ( Luvox ) , fluoxetine ( Prozac ) , sertraline ( Zoloft ) , paroxetine ( Paxil ) Wellbutrin SNRIs venlafaxine ( Effexor ) , duloxetine ( Cymbalta ) Participant take follow natural health product alter body weight appetite : ephedra , synephrine , green tea extract , daily use bulk fibre laxative ( e.g . psyllium , glucomannan ) Participant eligible enrolment medically supervised LCD program Wharton Medical Clinic ( WMC accept patient referral family physician . To eligible patient must BMI ≥ 30 ≥ 27 least one obesity relate comorbidity . ) Patient past history severe hypoglycaemia ( define Diabetes Control Complications Trial ( DCCT ) ) whether insulin , sulfonylureas nonsulfonylurea secretogogues Patient document hypoglycemic unawareness , whether insulin , sulfonylureas nonsulfonylurea secretogogues Achalasia ( i.e . difficulty swallow ) Patient take medication target GLP1 ( glucagonlike peptide1 ) include GLP1 analogue ( e.g . Byetta ( Exenatide ) , Victoza ( Liraglutide ) ) DPPIV inhibitor ( e.g . Januvia ( Sitagliptin ) , Onglyza ( Saxagliptin ) . Positive urine pregnancy test , pregnancy , breast feeding , hormonal contraceptive start last 6 month prior start study Absence highly effective method birth control female childbearing potential ( premenopausal surgically sterile ) OR plan use contraception duration study participation AND agree periodic urine pregnancy test study . ICH M3 define highly effective method birth control result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner . Substance abuse : tobacco ( include quit smoking last 12 month ) , Cannabis sativa , control substance use Any allergy study product ingredient include dairy , whey , rice , soy coconut . Labile uncontrolled hypertension ( SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg ) Current diagnosis history gastrointestinal diseases disorder ( exception Irritable Bowel Syndrome GERD discretion qualify investigator ) . Heart failure Substantial neurological psychological illness within last 6 month ( discretion qualify investigator ) Contraindications LCD 1. major surgery , time screening , plan take place study 2. history drug alcohol dependency within six month prior sign inform consent form . 3. history active malignancy ( exception discretion qualify investigator e.g . squamous cell carcinoma ) , chronic inflammatory disorder , chronic infection would interfere protocol completion 4. history CV event angina within 6 month ( exception stable angina discretion qualify investigator ) 5. history active gall bladder disease gallbladder remove 6. inflammatory bowel disease 7. type 1 diabetes 8. significant renal impairment eGFR &lt; 50 9. porphyria 10. cirrhosis 11. patient deem unable comprehend comply diet and/or , 12. unable attend program follow visit Participant fully understand instruction English . Any medical , social geographic condition , , opinion qualify investigator would allow safe completion protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>